Chlamydia Treatment
For uncomplicated genital chlamydia in non-pregnant adults, treat with either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days—both achieve approximately 97-98% cure rates and are equally effective. 1, 2, 3
First-Line Treatment Selection
Choose between the two first-line options based on these specific factors:
Azithromycin 1 g single dose is preferred when:
- Compliance with a 7-day regimen is questionable 1, 2
- Follow-up is unpredictable or unlikely 2
- Directly observed therapy is needed 1, 3
- Treating young adults or populations with erratic health-care-seeking behavior 2
Doxycycline 100 mg twice daily for 7 days is preferred when:
- Cost is a primary concern (significantly less expensive than azithromycin) 2
- The patient can reliably complete a 7-day course 2
- There is extensive clinical experience with this regimen 3
Critical Management Steps
Medication dispensing and observation:
- Dispense medications on-site whenever possible 1, 2
- Directly observe the first dose to maximize compliance 1, 2
Sexual abstinence requirements:
- Patients must abstain from all sexual intercourse for 7 days after initiating treatment 1, 2
- Continue abstinence until all sex partners have completed treatment 1, 2
Partner management (non-negotiable):
- All sex partners from the preceding 60 days must be evaluated, tested, and empirically treated 1, 2
- If last sexual contact was >60 days before diagnosis, still treat the most recent partner 1
- Failing to treat partners leads to reinfection in up to 20% of cases 1
Treatment During Pregnancy
Azithromycin 1 g orally as a single dose is the preferred treatment during pregnancy. 1, 2
Alternative options if azithromycin cannot be used:
- Amoxicillin 500 mg orally three times daily for 7 days 1, 2
- Erythromycin base 500 mg orally four times daily for 7 days 1, 2
Absolute contraindications in pregnancy:
Alternative Treatment Regimens (Only When First-Line Cannot Be Used)
Use these only when azithromycin and doxycycline are contraindicated or not tolerated:
- Levofloxacin 500 mg orally once daily for 7 days 1, 2
- Ofloxacin 300 mg orally twice daily for 7 days 1, 2
- Erythromycin base 500 mg orally four times daily for 7 days 1, 2
- Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1, 2
Important caveat: Erythromycin is less efficacious than azithromycin or doxycycline, and gastrointestinal side effects frequently lead to poor compliance. 1, 2, 3
Pediatric Dosing
For children ≥8 years weighing >45 kg:
- Azithromycin 1 g orally as a single dose, OR 1, 2
- Doxycycline 100 mg orally twice daily for 7 days 1, 2
For children <45 kg:
- Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 1, 2
For infants with chlamydial pneumonia (ages 1-3 months):
- Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 1
- Treatment effectiveness is approximately 80%; a second course may be needed 1
Follow-Up and Retesting
Test-of-cure is NOT recommended for non-pregnant patients treated with recommended regimens. 1, 2
- Treatment failure rates are extremely low: 0-3% in males, 0-8% in females 2
- Testing before 3 weeks post-treatment is unreliable due to false-positive results from dead organisms 1
Test-of-cure IS mandatory in these situations:
- All pregnant patients (test 3-4 weeks after treatment completion) 1, 2
- Questionable therapeutic compliance 1, 2
- Persistent symptoms 1, 2
- Suspected reinfection 1, 2
Reinfection screening (distinct from test-of-cure):
- All women with chlamydia should be retested approximately 3 months after treatment, regardless of whether partners were reportedly treated 1, 2
- Reinfection rates can reach 39% in some adolescent populations 1, 2
- Repeat infections carry elevated risk for pelvic inflammatory disease and other complications 1
Additional STI Testing
At the initial visit, patients diagnosed with chlamydia should be tested for:
Common pitfall: If gonorrhea is confirmed or prevalence is high in the patient population, always treat presumptively for both infections, as coinfection rates are substantial. 1